Impact of Insulin Bolus Reduction on Postprandial Blood Glucose Variations During Continuous and Intermittent Exercise in Patients with Type 1 Diabetes

Impact of insulin bolus reduction on blood glucose variation during two types of exercise (continuous vs intermittent) performed in the postprandial period in living patients with type 1 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202304590853621

Enrollment

Registered

2023-04-05

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

RED50

RED100

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age = 18 years heterogeneous sex (women and men), duration of diabetes = 1 year, using multiple daily injections (MDI) for a least 3 months, HbA1c result (less than 2 months) = 12% (108 mmol/mol).

Exclusion criteria

Exclusion criteria: presence of clinically significant microvascular complications: nephropathy (glomerular filtration rate <40 ml/min), neuropathy (gastroparesis specifically), or proliferative retinopathy, recent macrovascular events (<3 months), anemia or other abnormal blood test results, pregnancy, recent severe hypoglycemia (<2 weeks) , a medical situation that could interfere with the protocol

Design outcomes

Primary

Measure	Time frame
Decrease in plasma glucose levels during exercise (difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of exercise).	—

Secondary

Measure	Time frame
Secondary comparisons and endpoints For the exercise period only: 1) Percentage of time of plasma glucose levels spent below 4 mmol/L; 2) Decremental area under the curve (AUC) of plasma glucose levels; 3) AUC of plasma glucose levels 10 mmol/L; 8) Percentage of time of plasma glucose levels spent in target defined as between 4-10 mmol/L; 9) Mean time (minutes) to the first hypoglycemic event during the exercise period; 10) Amount of CHO needed to treat a hypoglycemic event. 11) Muscle vasodilatation. For the post-exercise period: 1) In the 4 hours following the exercise: a. Percentage of time of sensor glucose levels spent between 4 and 10 mmol/L; b. Percentage of time of sensor glucose levels spent 10 mmol/L; d. AUC of sensor glucose levels 10 mmol/L; d. AUC of sensor glucose levels < 4 mmol/L; e. Number of patients requiring an oral treatment for hypoglycemia; f. Total number of hypoglycemia episodes requiring treatment;	—

Measure

Time frame

Secondary comparisons and endpoints For the exercise period only: 1) Percentage of time of plasma glucose levels spent below 4 mmol/L; 2) Decremental area under the curve (AUC) of plasma glucose levels; 3) AUC of plasma glucose levels 10 mmol/L; 8) Percentage of time of plasma glucose levels spent in target defined as between 4-10 mmol/L; 9) Mean time (minutes) to the first hypoglycemic event during the exercise period; 10) Amount of CHO needed to treat a hypoglycemic event. 11) Muscle vasodilatation. For the post-exercise period: 1) In the 4 hours following the exercise: a. Percentage of time of sensor glucose levels spent between 4 and 10 mmol/L; b. Percentage of time of sensor glucose levels spent 10 mmol/L; d. AUC of sensor glucose levels 10 mmol/L; d. AUC of sensor glucose levels < 4 mmol/L; e. Number of patients requiring an oral treatment for hypoglycemia; f. Total number of hypoglycemia episodes requiring treatment;

—

Countries

Tunisia

Contacts

Public ContactWarda Lahoual

MSC

wardalahouel.doc@gmail.com+21692617461

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026